TPST
Tempest Therapeutics, Inc. NASDAQ Listed Nov 12, 2012$1.25
+0.00%
vs $1.25
Mkt Cap $5.2M
52w Low $1.23
0.2% of range
52w High $11.83
50d MA $1.71
200d MA $4.39
P/E (TTM)
-0.2x
EV/EBITDA
—
P/B
0.8x
Debt/Equity
1.2x
ROE
-393.8%
P/FCF
-0.2x
RSI (14)
33.30
ATR (14)
$0.06
Beta
-1.89
50d MA
$1.71
200d MA
$4.39
Avg Volume
139.5K
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
7000 Shoreline Court · Brisbane, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | BMO | -0.28 | -2.53 | -803.6% | 2.09 | -4.3% | -12.4% | -0.5% | -2.2% | +4.5% | -2.7% | — |
| May 13, 2026 | BMO | — | — | — | 1.92 | -1.0% | -4.2% | +13.6% | -12.4% | -0.5% | -2.2% | — |
| Mar 31, 2026 | BMO | -0.62 | -0.62 | +0.0% | 1.64 | +0.6% | -1.2% | -1.9% | +0.0% | -1.9% | +0.0% | — |
| Nov 5, 2025 | BMO | -3.27 | -0.79 | +75.8% | 9.95 | +0.5% | -4.1% | -0.2% | +2.8% | -1.7% | -9.6% | — |
| Aug 11, 2025 | BMO | -3.23 | -2.07 | +35.9% | 8.01 | -3.7% | +10.0% | +6.0% | +1.5% | +11.1% | -3.5% | — |
| May 13, 2025 | BMO | -3.71 | -3.16 | +14.8% | 6.79 | -1.9% | -3.5% | -0.8% | +5.4% | -2.8% | +0.6% | — |
| Mar 27, 2025 | BMO | -3.12 | -4.03 | -29.2% | 10.92 | -6.0% | -8.1% | -4.5% | -3.1% | +6.4% | -5.5% | — |
| Nov 12, 2024 | BMO | -4.81 | -5.33 | -10.8% | 14.04 | -13.3% | -10.5% | +0.3% | -8.2% | -4.8% | +2.1% | — |
| Aug 8, 2024 | BMO | -6.11 | -5.46 | +10.6% | 17.42 | +3.0% | -14.2% | -16.8% | +15.0% | +8.2% | +30.3% | — |
| May 9, 2024 | BMO | -5.72 | -4.68 | +18.2% | 45.11 | +2.0% | -6.3% | +0.9% | +3.7% | -0.6% | -4.7% | — |
| Mar 19, 2024 | BMO | -4.94 | -4.42 | +10.5% | 48.62 | +0.0% | +0.5% | -6.6% | +3.7% | +0.0% | +1.9% | — |
| Nov 8, 2023 | BMO | -7.15 | -6.24 | +12.7% | 36.66 | +22.3% | +16.3% | -1.8% | +7.1% | -7.8% | +3.8% | — |
| Aug 10, 2023 | BMO | -7.54 | -7.02 | +6.9% | 7.93 | +1.6% | +1.6% | +5.7% | +0.1% | -1.9% | -0.6% | — |
| May 10, 2023 | BMO | -8.58 | -7.15 | +16.7% | 26.78 | -6.8% | +2.9% | -0.9% | +3.8% | -6.9% | +0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 22 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.61 | $2.76 | +5.7% | +17.6% | -2.9% | -2.7% | +1.4% | -5.1% |
| Apr 10 | Scotiabank | Downgrade | Sector Outperform → Sector Perform | — | $7.15 | $7.25 | +1.4% | -18.0% | +6.1% | +11.9% | +7.2% | -2.8% |
| Apr 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $7.15 | $7.25 | +1.4% | -18.0% | +6.1% | +11.9% | +7.2% | -2.8% |
| Mar 28 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $10.92 | $10.27 | -6.0% | -8.1% | -4.5% | -3.1% | +6.4% | -5.5% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.92 | $10.27 | -6.0% | -8.1% | -4.5% | -3.1% | +6.4% | -5.5% |
| Nov 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.04 | $12.17 | -13.3% | -10.5% | +0.3% | -8.2% | -4.8% | +2.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.04 | $12.17 | -13.3% | -10.5% | +0.3% | -8.2% | -4.8% | +2.1% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.55 | $20.41 | +16.3% | -18.5% | -6.8% | +4.4% | +9.3% | -5.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.47 | $15.99 | +3.4% | +30.3% | -7.1% | +0.7% | +0.7% | +1.4% |
| Jun 21 | Piper Sandler | Maintains | Overweight → Overweight | — | $26.13 | $25.48 | -2.5% | +1.0% | +3.0% | -1.4% | +4.9% | +0.5% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.05 | $34.84 | -6.0% | -29.5% | +1.0% | +3.0% | -1.4% | +4.9% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.25 | $42.25 | +0.0% | +0.9% | +3.7% | -0.6% | -4.7% | -1.2% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.11 | $46.02 | +2.0% | -6.3% | +0.9% | +3.7% | -0.6% | -4.7% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.62 | $48.62 | +0.0% | +0.5% | -6.6% | +3.7% | +0.0% | +1.9% |
| Mar 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $43.94 | $44.46 | +1.2% | +0.0% | +0.3% | +1.2% | +6.1% | +6.3% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.12 | $27.69 | +787.5% | +3970.8% | -59.3% | -8.5% | +85.2% | +6.4% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.93 | $8.06 | +1.6% | +1.6% | +5.7% | +0.1% | -1.9% | -0.6% |
| Jun 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.85 | $18.98 | +0.7% | +0.7% | +0.7% | -5.4% | -3.6% | -11.2% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.05 | $24.57 | +2.2% | -12.1% | -5.9% | -5.9% | +0.7% | +0.7% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.78 | $24.96 | -6.8% | +2.9% | -0.9% | +3.8% | -6.9% | +0.5% |
| Apr 28 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $22.36 | $42.12 | +88.4% | +23.3% | +3.8% | -2.3% | -7.0% | +7.5% |
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.09 | $17.81 | +4.2% | +6.5% | -2.9% | +1.0% | +27.5% | +33.7% |
| Mar 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.09 | $17.81 | +4.2% | +6.5% | -2.9% | +1.0% | +27.5% | +33.7% |
| Feb 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.56 | $22.10 | -2.0% | +8.3% | -2.1% | +0.5% | +2.1% | -2.7% |
| Sep 15 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $29.38 | $31.72 | +8.0% | +4.4% | -3.4% | +1.3% | -8.2% | -3.3% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.44 | $37.05 | -1.0% | +4.5% | +4.3% | -2.2% | +1.3% | +15.1% |
| Oct 21 | William Blair | Maintains | Outperform → Outperform | — | $180.70 | $178.36 | -1.3% | -2.4% | -10.4% | -2.2% | -1.0% | -2.3% |
| Jul 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $314.47 | $327.60 | +4.2% | -14.9% | +9.4% | -13.7% | +1.9% | +0.5% |
| Jul 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $145.86 | $149.24 | +2.3% | +18.0% | -17.4% | -4.0% | +49.4% | +54.4% |
No insider trades available.
8-K
Tempest Therapeutics, Inc. -- 8-K Filing
Jun 23
8-K
Tempest Therapeutics, Inc. -- 8-K Filing
Jun 2
8-K · 5.02
!!! Very High
Tempest Therapeutics, Inc. -- 8-K 5.02: Executive Change
May 29
8-K · 5.02
!!! Very High
Tempest Therapeutics, Inc. -- 8-K 5.02: Executive Change
May 22
8-K · 2.02
!! High
Tempest Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K
Unknown — 8-K Filing
Tempest's acquisition of dual-targeting CAR-T assets and positive interim REDEEM-1 trial data for TPST-2003 strengthen its clinical pipeline and validate its technology, potentially positioning the company for higher valuations if pivotal trials succeed.
Mar 30
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
TPST's private equity placement dilutes existing shareholders but provides cash for operations or growth, so investors should monitor whether management deploys capital effectively to justify the dilution.
Mar 23
8-K
Tempest Therapeutics, Inc. -- 8-K Filing
Tempest Therapeutics' investigational therapy achieved 100% complete response rate in early multiple myeloma patients with favorable safety, supporting its 2026 U.S. registration submission plans.
Feb 25
8-K · 7.01
! Medium
Tempest Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Tempest Therapeutics disclosed a corporate presentation for investor review, providing updated information about the company's business strategy and financial position.
Feb 11
8-K · 2.01
!!! Very High
Tempest Therapeutics, Inc. -- 8-K 2.01: Acquisition Completed
Tempest Therapeutics completed an acquisition, though specific target details and financial terms require reviewing the full filing for investor impact assessment.
Feb 6
Institutional (13F) — Top 9
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 233,888 | $384K | New | Mar 2026 |
| 2 | Fmr Llc | 33,225 | $54K | — | Mar 2026 |
| 3 | Northern Trust Corp | 14,053 | $23K | — | Mar 2026 |
| 4 | Morgan Stanley | 4,116 | $12K | Reduced | Dec 2025 |
| 5 | Ubs Group Ag | 4,533 | $7K | Reduced | Mar 2026 |
| 6 | Federation Des Caisses Desjardins Du Quebec | 292 | $479 | — | Mar 2026 |
| 7 | Jpmorgan Chase & Co | 5 | $8 | New | Mar 2026 |
| 8 | Bnp Paribas Financial Markets | 3 | $5 | — | Mar 2026 |
| 9 | Royal Bank Of Canada | 27 | — | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 24,318 | $55K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 7,495 | $17K | Feb 2026 |
| 3 | Dimensional US Core Equity 1 ETF | 3,985 | $11K | Jan 2026 |
| 4 | Fidelity Series Total Market Index Fund | 4,421 | $10K | Feb 2026 |
| 5 | Dimensional U.S. Core Equity 2 ETF | 107 | $291 | Jan 2026 |
Valuation
Market Cap
$5.2M
Enterprise Value
$4.4M
P/E (TTM)
-0.20x
Forward P/E
—
PEG Ratio
-0.00x
P/B
0.78x
P/S
—
P/FCF
-0.19x
EV/EBITDA
—
Shares Out
4.1M
Financials (TTM)
Revenue
$0
Net Income
-$43.1M
EBITDA
-$42.8M
Free Cash Flow
-$26.8M
Op Cash Flow
-$26.8M
EPS Basic
$-6.33
EPS Diluted
$-6.21
EPS Forward
$-1.34
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$16.9M
Total Liab.
$10.3M
Total Equity
$6.7M
Cash
$7.7M
LT Debt
$6.9M
Book Value/Sh
$1.61
Debt/Equity
1.22x
Current Ratio
2.50
Quick Ratio
2.50
Returns & Growth
ROE
-393.8%
ROA
-155.1%
ROIC
-179.4%
Rev Growth YoY
+0.0%
EPS Growth YoY
-322.0%
Price Returns
2W
-26.8%
1M
-23.1%
3M
-32.9%
6M
-52.2%
12M
-74.3%
Technicals
52W High
$11.83
52W Low
$1.23
50d MA
$1.71
200d MA
$4.39
RSI (14)
33.30
ATR (14)
$0.06
Beta
-1.89
Avg Volume
139K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 27, 2026 5:26am
· Source: financialmodelingprep.com